[go: up one dir, main page]

PE20091369A1 - Metodo para la preparacion de acido montelukast en un medio liquido ionico - Google Patents

Metodo para la preparacion de acido montelukast en un medio liquido ionico

Info

Publication number
PE20091369A1
PE20091369A1 PE2008001742A PE2008001742A PE20091369A1 PE 20091369 A1 PE20091369 A1 PE 20091369A1 PE 2008001742 A PE2008001742 A PE 2008001742A PE 2008001742 A PE2008001742 A PE 2008001742A PE 20091369 A1 PE20091369 A1 PE 20091369A1
Authority
PE
Peru
Prior art keywords
ethyl
preparation
liquid medium
ionic liquid
montelukast acid
Prior art date
Application number
PE2008001742A
Other languages
English (en)
Inventor
Chul-Hyun Park
Eun-Ju Park
Choong-Hahn Kim
Suk Man Jang
Eun Jung Lim
Young Kil Chang
Gwan Sun Lee
Jaeheon Lee
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40549354&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091369(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of PE20091369A1 publication Critical patent/PE20091369A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Quinoline Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE REFIERE A UN METODO PARA PREPARAR ACIDO MONTELUKAST, QUE COMPRENDE: ACOPLAR UN COMPUESTO DE TIOL DE FORMULA (2) CON UN MONTELUKAST INTERMEDIO DE FORMULA (3) EN PRESENCIA DE UNA BASE TAL COMO T-BUTILATO DE POTASIO, T-BUTILATO DE SODIO, NaH, NaOH Y KOH, EN UN MEDIO QUE CONTENGA UN COMPUESTO LIQUIDO IONICO SELECCIONADO DE 1-ETIL-3-METILIMIDAZOLIUM BROMURO, 1-ETIL-3-METILIMIDAZOLIUM HEXAFLUOROFOSFATO, N-BUTIL-N-METILPIRROLIDIUM, ENTRE OTROS; DONDE R1 ES H, METILO O ETILO. DICHO COMPUESTO BLOQUEA O INHIBE LA SINTESIS DE LEUCOTRIENOS Y ES DE UTILIDAD PARA TRASTORNOS INFLAMATORIOS
PE2008001742A 2007-10-09 2008-10-09 Metodo para la preparacion de acido montelukast en un medio liquido ionico PE20091369A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020070101486A KR101072896B1 (ko) 2007-10-09 2007-10-09 이온성 액체 매개체를 이용한 몬테루카스트산의 제조 방법

Publications (1)

Publication Number Publication Date
PE20091369A1 true PE20091369A1 (es) 2009-10-01

Family

ID=40549354

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2013000260A PE20131219A1 (es) 2007-10-09 2008-10-09 Metodo para la preparacion de acido montelukast en un medio liquido ionico
PE2008001742A PE20091369A1 (es) 2007-10-09 2008-10-09 Metodo para la preparacion de acido montelukast en un medio liquido ionico

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2013000260A PE20131219A1 (es) 2007-10-09 2008-10-09 Metodo para la preparacion de acido montelukast en un medio liquido ionico

Country Status (18)

Country Link
US (1) US8426599B2 (es)
EP (1) EP2195295B1 (es)
JP (1) JP5210389B2 (es)
KR (1) KR101072896B1 (es)
CN (1) CN101808998B (es)
AR (1) AR068755A1 (es)
CA (1) CA2701912C (es)
CL (1) CL2008002996A1 (es)
DK (1) DK2195295T3 (es)
ES (1) ES2398732T3 (es)
HR (1) HRP20130103T1 (es)
MX (1) MX2010001864A (es)
PE (2) PE20131219A1 (es)
PL (1) PL2195295T3 (es)
PT (1) PT2195295E (es)
RU (1) RU2436774C1 (es)
TW (1) TWI350284B (es)
WO (1) WO2009048236A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP1000425A2 (en) 2010-08-11 2012-03-28 Richter Gedeon Nyrt Process for the production of montelukast sodium
CN103570618A (zh) * 2013-09-30 2014-02-12 浙江车头制药股份有限公司 一种孟鲁司特钠盐的制备方法
CN105294556A (zh) * 2014-06-06 2016-02-03 上海迪赛诺化学制药有限公司 一种制备孟鲁司特酸的方法
US10966943B2 (en) 2018-09-06 2021-04-06 Innopharmascreen Inc. Methods and compositions for treatment of asthma or parkinson's disease
KR102181155B1 (ko) * 2019-09-26 2020-11-20 대봉엘에스 주식회사 이온성 액체를 매개로 한 에피나코나졸의 신규 제조방법
CN111961083B (zh) * 2020-08-27 2022-11-25 鲁南制药集团股份有限公司 一种孟鲁司特钠中间体化合物
CN111892535B (zh) * 2020-08-27 2023-04-11 鲁南制药集团股份有限公司 一种孟鲁司特钠的合成方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE165088T1 (de) 1990-10-12 1998-05-15 Merck Frosst Canada Inc Ungesättigte hydroxyalkylchinolinsäuren als leukotrien-antagonisten
MY107767A (en) * 1992-04-10 1996-06-15 Merck Frosst Canada Inc Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists
TW416948B (en) 1993-12-28 2001-01-01 Merck & Co Inc Process for the preparation of leukotriene antagonists
US5523477A (en) 1995-01-23 1996-06-04 Merck & Co., Inc. Process for the preparation of 1-(thiomethyl)-cyclopropaneacetic acid
MXPA06008584A (es) * 2004-01-30 2007-04-16 Teva Pharma Polimorfos de acido libre de montelukast.
ES2327762T3 (es) 2004-04-21 2009-11-03 Teva Pharmaceutical Industries Ltd Procedimiento para preparar montelukast sodico.
JP2006089463A (ja) * 2004-08-24 2006-04-06 Sumitomo Chemical Co Ltd アリールエーテル類の製造方法
WO2006064269A2 (en) * 2004-12-17 2006-06-22 Cipla Limited Salts of leukotriene antagonist montelukast
GB0500029D0 (en) * 2005-01-04 2005-02-09 Univ Belfast Basic ionic liquids
CN101326275B (zh) * 2005-10-07 2013-06-05 阿拉巴马大学 多功能离子液体组合物
EP1783117A1 (en) 2005-11-04 2007-05-09 Esteve Quimica, S.A. Process for the preparation of a leukotriene antagonist and intermediates thereof
EP1968943B1 (en) 2005-12-13 2013-01-23 MSN Laboratories Limited An improved process for the preparation of montelukast and its pharmaceutically acceptable salts
EP1968942A4 (en) * 2005-12-23 2010-06-02 Glade Organics Private Ltd IMPROVED PROCESS FOR THE PREPARATION OF SODIUM MONTELUKAST
IL181607A0 (en) * 2006-02-27 2007-07-04 Chemagis Ltd Novel process for preparing montelukast and salts thereof
KR100774088B1 (ko) 2006-12-14 2007-11-06 한미약품 주식회사 몬테루카스트의 제조방법 및 이에 사용되는 중간체

Also Published As

Publication number Publication date
KR20090036349A (ko) 2009-04-14
EP2195295A4 (en) 2011-04-13
CL2008002996A1 (es) 2009-04-13
JP5210389B2 (ja) 2013-06-12
CN101808998B (zh) 2012-10-24
MX2010001864A (es) 2010-03-15
US8426599B2 (en) 2013-04-23
KR101072896B1 (ko) 2011-10-17
EP2195295B1 (en) 2013-01-23
US20110105757A1 (en) 2011-05-05
PE20131219A1 (es) 2013-11-16
CA2701912C (en) 2013-04-02
TW200920737A (en) 2009-05-16
JP2011500555A (ja) 2011-01-06
PT2195295E (pt) 2013-02-28
RU2436774C1 (ru) 2011-12-20
TWI350284B (en) 2011-10-11
CA2701912A1 (en) 2009-04-16
WO2009048236A1 (en) 2009-04-16
AR068755A1 (es) 2009-12-02
EP2195295A1 (en) 2010-06-16
DK2195295T3 (da) 2013-05-06
ES2398732T3 (es) 2013-03-21
CN101808998A (zh) 2010-08-18
PL2195295T3 (pl) 2013-06-28
HRP20130103T1 (hr) 2013-02-28

Similar Documents

Publication Publication Date Title
PE20091369A1 (es) Metodo para la preparacion de acido montelukast en un medio liquido ionico
PA8855501A1 (es) Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable
CL2010001603A1 (es) Metodo para la flotacion por espuma que comprende mezclar una suspension de la mena con un colector, al menos un agente espumante y un depresor, el colector comprende al menos dos estructuras c10-c24 entrecruzados por un enlace eter y un valor de acido entre 50 mg de koh/g y 400 mg de koh/g; composicion y kit.
PE20120250A1 (es) Composicion farmaceutica que comprende derivados de glucopiranosil difenilmetano, forma farmaceutica de la misma, procedimiento para su preparacion
AR068501A1 (es) Formulacion de resina fenolica y recubrimientos para productos abrasivos
PE20081816A1 (es) Composiciones para bebidas comprendiendo polilisina y por lo menos un acido debil
WO2009063250A3 (en) Personal care composition
EA200901609A1 (ru) Амиды пиразолкарбоновой кислоты, применимые в качестве микробиоцидов
CL2011001586A1 (es) Metodo que comprende una composicion que contiene sulfoximida de 6-haloalquilpiridin-3-il-alquilo n-sustituida; composicion comprendiendo una mezcla estereoisomera de dicha sulfoximida en una formulacion farmaceutica acuosa.
ES2531190T3 (es) Método para producir un compuesto de 4-oxoquinolina
AR074270A1 (es) Composicion de champu concentrada
UY31883A (es) Nuevo procedimiento de síntesis de 7,8-dimetoxi-1, 3-dihidro-2h-3-benzazepin-2-ona, y aplicación en la síntesis de ivabradina y de sus sales de adición a un ácido farmacéuticamente aceptable
UY32309A (es) Proceso para la fabricación de derivados del ácido 5-metoximetilpiridin-2,3-dicarboxilico sustituido
WO2007107966A3 (en) Hydrogenated castor oil based compositions as a replacement for petrolatum
AR082776A1 (es) Estabilizacion de hormona foliculo estimulante (fsh)
MX388431B (es) Composicion para uso en la conduccion de operaciones de fondo de pozo en pozos de petroleo y gas.
TW201129536A (en) Ether compound, lubricant containing same, and composition for lubricant containing same
NZ601805A (en) Method for preparing tetrazole methanesulfonic acid salts, and novel compound used in same
MX2012000767A (es) Composicion y metodo.
BR112014026853A2 (pt) corante que absorve uv polimerizável estável para lente intraocular
EA201101147A1 (ru) Новый способ синтеза ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
AU2014352354B2 (en) Zirconium dispersed-particle gel combination flooding system and preparation method thereof
MX2012001155A (es) 2-(3-alquiltiobenzoil)ciclohexanodionas y su uso como herbicidas.
EA201000398A1 (ru) Новый способ синтеза ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
BR112012033599A2 (pt) novos derivados de tetrahidroquinolina.

Legal Events

Date Code Title Description
FC Refusal
AE Restoration of lapsed or forfeited application
FG Grant, registration
FD Application declared void or lapsed